ERBB2 and non-small cell lung carcinoma: Thus, by targeting HER2-positive tumor cell populations, T-DXd provides a more comprehensive approach to tumor eradication, particularly in advanced HER2-mutant NSCLC, where conventional therapies have shown limited success.